Last Update: Oct 15, 2024
A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study
ClinicalTrials.gov Identifier:
NCT05161195
Novartis Reference Number:CLEE011A2412B
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This is an open-label, multi-center, roll-over study to evaluate the long term safety of
ribociclib in combination with other drugs in participants who are participating in a
Novartis sponsored global study, that has fulfilled requirements for its primary
objective(s), and who in the opinion of the Investigator, would benefit from continued
treatment. The purpose of this study is to evaluate long-term safety and provide continued treatment
to participants who are currently receiving ribociclib in combination with other drugs in
a parent study, that has fulfilled requirements for its primary objective(s), and in the
opinion of the Investigator, would benefit from continuing treatment at time of
discontinuation from the parent study

Metastatic Breast Cancer
Phase4
Recruiting
137
Jul 07, 2022
Feb 16, 2028
All
18 Years - (Adult, Older Adult)

Interventions

Drug

Anastrozole

Participants continue ribociclib in combination with anastrozole as was administered in their parent study
Drug

Fulvestrant

All participants continue ribociclib in combination with fulvestrant as was administered in their parent study
Drug

Goserelin

Participants continue ribociclib in combination with goserelin as was administered in their parent study
Drug

Letrozole

Participants continue ribociclib in combination with letrozole as was administered in their parent study
Drug

Ribociclib

Participants continue ribociclib as was administered in their parent study
Drug

Tamoxifen

Participants continue ribociclib in combination with tamoxifen as was administered in their parent study

Eligibility Criteria

Key inclusion Criteria:

1. Currently participating in a Novartis sponsored global study (parent study),
receiving treatment with ribociclib in combination with other drugs, and the parent
study has fulfilled its primary objective(s)

2. Must have been receiving treatment with ribociclib for at least 6 cycles in the
parent study

3. Currently has evidence of clinical benefit as determined by the Investigator

Key exclusion Criteria:

1. Permanent discontinuation of ribociclib in the parent study

2. Currently has unresolved toxicities for which ribociclib dosing has been interrupted
in the parent study 3. Local access to commercially available ribociclib and
reimbursed

Other protocol-defined inclusion/exclusion criteria may apply at the end

Novartis Investigative Site

Recruiting

San Juan,J5402dil,Argentina

Novartis Investigative Site

Recruiting

Ijui,RS,98700-000,Brazil

Novartis Investigative Site

Recruiting

Florianopolis,SC,88034-000,Brazil

Novartis Investigative Site

Recruiting

Sao Paulo,SP,01317 000,Brazil

Novartis Investigative Site

Recruiting

Sao Paulo,SP,03102,Brazil

Novartis Investigative Site

Recruiting

Sao Jose do Rio Preto,15090 000,Brazil

Novartis Investigative Site

Recruiting

Sao Paulo,01255-000,Brazil

Novartis Investigative Site

Recruiting

Natal,RN,59075 740,Brazil

Novartis Investigative Site

Recruiting

San Jose,95008,Costa Rica

Novartis Investigative Site

Recruiting

Trujillo,La Libertad,13011,Peru

Novartis Investigative Site

Recruiting

San Borja,Lima,41,Peru

Highlands Oncology Group

Recruiting

Fayetteville,Arkansas,72703,United States

Maddie Beck
+1 479 587 1700
Joseph Thaddeus Beck

University Hospitals of Cleveland Seidman Cancer Center

Recruiting

Cleveland,Ohio,44106,United States

Crystal Moore
Cynthia Owusu

Northern Light Mercy Hospital

Recruiting

Portland,Maine,04102,United States

207-553-6868
Anna Niegowska

Beverly Hills Cancer Center

Recruiting

Beverly Hills,California,90211,United States

Linnea Chap
Noel Vargas
310-432-8900

Oklahoma Cancer Specialists and Research Institute

Recruiting

Tulsa,Oklahoma,74136,United States

Andrea Niceley
918-292-8085
Kevin Weibel

Englewood Health

Recruiting

Englewood,New Jersey,07631,United States

Audrey Ades
201-568-5250
Jill Morrison

Duly Health and Care

Recruiting

Plainfield,Illinois,60585,United States

Melissa Meyer
815-730-3098
Nafisa Burhani

Ironwood Cancer and Research Centers

Recruiting

Chandler,Arizona,85224,United States

Mikhail I Shtivelband
Tiffany Walas
480-855-2225

The Valley Hospital-Luckow Pavillion

Recruiting

Paramus,New Jersey,07652,United States

201-634-5792
Eleonora Teplinsky

Indian Univ Health Goshen Center forCancer

Recruiting

Goshen,Indiana,46526,United States

Bolanle Adepoju
Jeremy Messick
574-535-2888

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

+41613241111

Novartis Pharmaceuticals

1-888-669-6682